Category:
Medical Studies
Analysis of time to recurrence in the ATAC (arimidex, tamoxifen, alone or in combination) trial acc
Background: The ATAC trial randomized 9366 postmenopausal women with early breast cancer to 5 years of treatment with anastrozole (A) or tamoxifen (T) or the combination (C) of A+T. After 47 months median follow-up the hazard ratio (HR) for disease-free survival was 0.86 (0.760.99, p=0.03) in the overall population and 0.82 (0.700.96, p=0.014) in the estrogen receptor (ER) and/or progesterone receptor (PgR) positive group, in favor of A when compared with T.
|
2003/12/03 |
Category:
Definition & Diagnosis
Ductal carcinoma in situ (DCIS)
Treatments and drugs
Treatment of DCIS has a high likelihood of success, in most instances removing the tumor and preventing any recurrence, particularly a recurrence that spreads beyond the original site. The challenge is to avoid either overtreating or undertreating the condition.
Treatment options for DCIS include:
- Lumpectomy only
- Lumpectomy and radiation therapy
- Lumpectomy and the drug tamoxifen
- Simple mastectomy
Surgery
If you're diagnosed with DCIS, one of the first decisions you'll have to make is whether to treat the condition with breast-conserving surgery (lumpectomy) or breast-removing surgery (mastectomy).
|
2007/06 |
Category:
Medical Studies
19th Annual Miami Brest Cancer Conference
What is the optimal local and systemic therapy for DCIS? Do all DCIS patients need radiation therapy? What is the optimal endocrine therapy for DCIS?
|
2001 |
Category:
Medical Studies
A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Ea
Background In hormone-dependent breast cancer, five years of postoperative tamoxifen therapy — but not tamoxifen therapy of longer duration — prolongs disease-free and overall survival. The aromatase inhibitor letrozole, by suppressing estrogen production, might improve the outcome after the discontinuation of tamoxifen therapy.
|
|
Category:
Medical Studies
A retrospective review of wide excision alone for ductal carcinoma in situ (DCIS) of the breast
Background: The standard treatment for ductal carcinoma in situ (DCIS) of the breast today is wide excision (WE) followed by radiotherapy.
|
2004/07/15 |
Category:
Definition & Diagnosis
A.P.John institute for cancer research
The following stages are used for breast cancer:
Stage 0 (carcinoma in situ)
There are 2 types of breast carcinoma in situ:
* Ductal carcinoma in situ (DCIS) is a noninvasive, precancerous condition in which abnormal cells are found in the lining of a breast duct. The abnormal cells have not spread outside the duct to other tissues in the breast. In some cases, DCIS may become invasive cancer and spread to other tissues, although it is not known at this time how to predict which lesions will become invasive.
* Lobular carcinoma in situ (LCIS) is a condition in which abnormal cells are found in the lobules of the breast. This condition seldom becomes invasive cancer; however, having lobular carcinoma in situ in one breast increases the risk of developing breast cancer in either breast.
Stage I to Stage IV
|
undated |
Category:
Miscellaneous
Accepting the Nude You
If your self-image has been hurt by your breast cancer, you need to work at getting back a positive view of yourself.
Are you going to great lengths not to look at the scars on your chest? Your reluctance to face the scars is understandable. But experts on healing suggest it's important to get past this attitude.
|
|
Category:
Medical Studies
Adjuvant radiation therapy for DCIS
Omission of breast radiation after breast conservation surgery is associated with higher incidence of recurrence rate. This is true for both ductal carcinoma in situ and invasive breast cancer.
|
|
Category:
Medical Studies
Adjuvant Therapy for All Patients With Breast Cancer?
In this issue of the Journal, Fisher et al. (1) from the National Surgical Adjuvant Breast and Bowel Project (NSABP) provide a retrospective analysis of the prognosis and treatment of patients with tumors 1 cm or less and negative axillary lymph nodes. They address a critical question about adjuvant therapy decision making: whether or not these therapies should be applied to patients with tumors smaller than 1 cm.
|
|
Category:
Definition & Diagnosis
Almac Diagnostics Announces Pioneering Genetic Research On Ductal Carcinoma In Situ (DCIS) Using Bre
Almac Diagnostics has announced a major study analysing ductal carcinoma in situ tissue samples using its novel Breast Cancer DSA™ microarray. DSA™ research tools focus on the transcriptome of an individual disease, in this case breast cancer, and contain significant additional data, relevant to the disease of interest that is not available on other generic microarrays. The study will be conducted in collaboration with Prof Adrian Harris, Cancer Research UK and Professor of Medical Oncology at the University of Oxford.
|
2007/08 |
Category:
Miscellaneous
Alternative/Complementary Medicine
An "alternative" therapy is a treatment that is used in place of traditional medicine. A "complementary" therapy is a treatment that is used as a supplement to traditional medicine. Alternative and complementary medicines have become increasingly popular in recent years. According to the National Institutes of Health’s National Center for Alternative and Complementary Medicine (NCCAM), Americans spent more than $27 billion on alternative or complementary therapies in 1997.
|
|
Category:
Miscellaneous
American Association for Cancer Research
Home Site
|
|
Category:
Medical Studies
An interim analysis of a prospective multi-institutional cohort study: quantitative real-time RT-PCR
The clinical relevance of molecular detection of micrometastatic breast cancer in sentinel and axillary lymph nodes has not been established.
|
2003/12/03 |
Category:
Diet & Exercise
Annals of Surgical Oconlolgy
Cancer Site
|
|
Category:
Miscellaneous
Annie Appleseed Project
Many articles on breast cancer...and...specific articles on DCIS
Some examples:
Results of a study very low mortality with DCIS/other DCIS info
Lumpectomy=Mastectomy for DCIS
Salvage Treatment
7th International Conference on Adjuvant Therapy
Risk Factors Subseq Invasive Bca
Management of DCIS
Tumor Markers Correlate w/Grade
Current Treatment of DCIS
Value of Lumpectomy Margin Assess
LCIS
DCIS Diagnosed 20% of Time
Mucinous Cancers
Metaplastic Bca: Path/Outcomes
Squamous Cell Ca of the Breast
Smoking & Radiation Therapy
DCIS Issues - SABCS 2006
|
2007/07 |
Category:
Miscellaneous
Are You Considering Using Complementary and Alternative Medicine (CAM)?
Decisions about your health care are important--including decisions about whether to use complementary and alternative medicine (CAM). The National Center for Complementary and Alternative Medicine (NCCAM) has developed this fact sheet to assist you in your decisionmaking about CAM. It includes frequently asked questions, issues to consider, and a list of sources for further information.
|
|
Category:
Medical Studies
Aromatase Inhibitors in Breast Cancer: An Update
Background: Tamoxifen has been the endocrine treatment of choice for patients with breast cancer. The development of selective aromatase inhibitors has offered an alternative management approach for patients in whom a hormonal approach is indicated.
*Registration Required, Free*
|
2003/02/10 |
Category:
Miscellaneous
BC Cancer Agency
Site Home - British Columbia Cancer Agency
|
|
Category:
Miscellaneous
Behind the Cancer Headlines
Provides daily news articles on the latest advances in breast cancer research and treatment options.
|
|
Category:
Medical Studies
Biological Behavior of Human Breast Cancer Micrometastases
Purpose: Clinically undetectable micrometastases may account for disease recurrence in breast cancer patients after variable disease-free intervals. However, little is known about the cellular mechanisms controlling human breast cancer micrometastases. We compared tumor proliferation rate, apoptotic index, and angiogenesis in human breast cancer micrometastases with those of macroscopic axillary lymph node metastases.
|
|